Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 5
2004 1
2005 7
2006 8
2007 8
2008 11
2009 5
2010 4
2011 16
2012 3
2013 3
2014 3
2015 3
2016 5
2017 3
2018 8
2019 6
2020 13
2021 22
2022 13
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Results by year

Filters applied: . Clear all
Page 1
Inhibiting the Keap1/Nrf2 Protein-Protein Interaction with Protein-Like Polymers.
Carrow KP, Hamilton HL, Hopps MP, Li Y, Qiao B, Payne NC, Thompson MP, Zhang X, Magassa A, Fattah M, Agarwal S, Vincent MP, Buyanova M, Bertin PA, Mazitschek R, Olvera de la Cruz M, Johnson DA, Johnson JA, Gianneschi NC. Carrow KP, et al. Among authors: vincent mp. Adv Mater. 2024 Jan 19:e2311467. doi: 10.1002/adma.202311467. Online ahead of print. Adv Mater. 2024. PMID: 38241649
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study.
Danto SI, Tsamandouras N, Reddy P, Gilbert S, Mancuso J, Page K, Peeva E, Vincent MS, Beebe JS. Danto SI, et al. Among authors: vincent ms. J Clin Pharmacol. 2024 May;64(5):529-543. doi: 10.1002/jcph.2360. Epub 2023 Oct 30. J Clin Pharmacol. 2024. PMID: 37772436 Clinical Trial.
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, Vincent MS, Sun Q, Sikirica V, Winnette R, Qiu R, Li G, Feng G, Beebe JS, Martin DA. Mease P, et al. Among authors: vincent ms. Arthritis Rheumatol. 2023 Aug;75(8):1370-1380. doi: 10.1002/art.42519. Epub 2023 Jun 22. Arthritis Rheumatol. 2023. PMID: 37194394 Free article. Clinical Trial.
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation.
Li W, Crouse KK, Alley J, Frisbie RK, Fish SC, Andreyeva TA, Reed LA, Thorn M, DiMaggio G, Donovan CB, Bennett D, Garren J, Oziolor E, Qian J, Newman L, Vargas AP, Kumpf SW, Steyn SJ, Schnute ME, Thorarensen A, Hegen M, Stevens E, Collinge M, Lanz TA, Vincent F, Vincent MS, Berstein G. Li W, et al. Among authors: vincent ms. J Pharmacol Exp Ther. 2023 Jul;386(1):80-92. doi: 10.1124/jpet.122.001452. Epub 2023 May 4. J Pharmacol Exp Ther. 2023. PMID: 37142443
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Landis MN, Smith SR, Berstein G, Fetterly G, Ghosh P, Feng G, Pradhan V, Aggarwal S, Banfield C, Peeva E, Vincent MS, Beebe JS, Tarabar S. Landis MN, et al. Among authors: vincent ms. Br J Dermatol. 2023 Jul 7;189(1):33-41. doi: 10.1093/bjd/ljad098. Br J Dermatol. 2023. PMID: 36972293 Clinical Trial.
152 results